SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report, dated December 21, 2022, details a material definitive agreement and unregistered sales of equity securities by BioSig Technologies, Inc. The company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM. The report focuses on a private placement transaction (December PIPE) executed on December 21, 2022, and references a prior transaction from November 2022.
Key Financial Metrics and Transaction Details
The filing discloses specific capital raise figures but does not provide comprehensive financial statements, revenue, profit, or cash flow data for the reporting period.
- December 2022 Capital Raise: The company sold 2,161,598 shares of common stock at $0.508 per share and warrants to purchase 1,080,799 shares at an exercise price of $0.4455 per share.
- Total Consideration Received: $1,098,091.79.
- November 2022 Capital Raise (Prior Period): The company sold 3,541,469 shares at $0.41 per share for total consideration of $1,452,000.
- Warrant Terms: Warrants issued in both transactions become exercisable six months after issuance and expire five and one-half years after issuance.
- Debt and Liquidity: The filing text does not provide clear values for total debt, cash balances, or liquidity ratios outside of the proceeds from these specific equity sales.
Material Changes and Unusual Items
The primary material change is the dilution of existing shareholders due to the issuance of new common stock and warrants in the December and November PIPE transactions. The company issued additional warrants to Laidlaw & Company (UK) Ltd. as compensation for engagement services related to these financings:
- Laidlaw Warrants (Nov PIPE): 60,976 shares at $0.41 exercise price.
- Laidlaw Warrants (Dec PIPE): 49,213 shares at $0.4455 exercise price.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, revenue outlook, or management commentary regarding future operational performance. The transaction was conducted in reliance on exemptions from registration under Section 4(a)(2) and Regulation D of the Securities Act of 1933. Standard risks associated with private placements, including potential dilution and the terms of the warrants, are inherent to the transaction described.
Key Facts for Investor Verification
- Verify the total number of outstanding shares post-transaction to assess dilution impact.
- Confirm the current cash position and burn rate to determine runway following the $1.1 million raise.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and restrictions.
- Monitor the exercise dates for the warrants issued in November and December 2022.
- Check for any subsequent filings regarding the use of proceeds from the December PIPE.